Business
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an early market leader in cutting-edge, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announces the launch and commercial availability of its OneTest for Longevity solution.
About this update from 20/20 Biolabs, Inc.
[{"type":"image","alt":"20/20 Biolabs Inc.","displaySize":"","headline":null,"caption":"20/20 Biolabs Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":244,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9sR3D0W2q_.DygCdr.xgmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190","width":244,"height":159}},"lazy":false},{"type":"text","content":"Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights","length":187,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an early market leader in cutting-edge, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announces the launch and commercial availability of its OneTest for Longevity solution. The solution uses IBM watsonx.ai – an integrated AI application development studio – to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase.","length":553,"tagName":"p"},{"type":"text","content":"The OneTest for Longevity solution uses IBM watsonx.ai* to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks.","length":379,"tagName":"p"},{"type":"text","content":""We are excited to partner with DAISource to bring our vision of AI-enabled health solutions to life," said Jonathan Cohen, CEO of 20/20 BioLabs. "This collaboration enabled us to leverage DAISource's expertise in deploying enterprise-grade AI capabilities from IBM to develop a scalable and secure solution that can make a meaningful impact on public health."","length":384,"tagName":"p"},{"type":"text","content":""Our collaboration with 20/20 BioLabs represents a significant step forward in bringing AI capabilities to hea...